A LinkedIn post from Forge Biologics highlights the company’s participation in the Gene Therapy Institute’s 2nd Annual Gene Therapy Symposium in Columbus. The post describes an active local gene therapy community where stakeholders shared challenges and signaled visible momentum across the field.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Forge team member Danielle Sexton presented a poster focused on supporting the transition from research-scale work to scalable manufacturing. This emphasis on partnering with researchers and developers at a critical translational stage suggests Forge is positioning its contract development and manufacturing capabilities to capture demand as gene therapy programs advance toward commercialization.
For investors, the content implies ongoing business development efforts and deeper integration into the regional and broader gene therapy ecosystem. Strong ties to early-stage innovators and academic or institute-led research may help Forge build a pipeline of future manufacturing engagements, potentially supporting longer-term revenue visibility if these collaborations mature into formal contracts.